Targeting the Brain with Nanomedicine

Author(s): Felix Rueda, Luis J. Cruz*

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 13 , 2017

Become EABM
Become Reviewer
Call for Editor


Herein, we review innovative nanomedicine-based approaches for treating, preventing and diagnosing neurodegenerative diseases. We focus on nanoscale systems such as polymeric nanoparticles (NPs), liposomes, micelles and other vehicles (e.g. dendrimers, nanogels, nanoemulsions and nanosuspensions) for targeted delivery of bioactive molecules to the brain. To ensure maximum selectivity for optimal therapeutic or diagnostic results, researchers must employ delivery systems that are non-toxic, biodegradable and biocompatible. This entails: (i) use of “safe” materials, such as polymers or lipids; (ii) targeting to the brain and, specifically, to the desired active site within the brain; (iii) controlled release of the loaded agent; and (iv) use of agents that, once released into the brain, will exhibit the desired pharmacologic activity. Here, we explore the design and preclinical use of representative delivery systems that have been proposed to date. We then analyze the principal challenges that have delayed clinical application of these and other approaches. Lastly, we look at future developments in this area, addressing the needs for increased penetration of the blood brain barrier (BBB), enhanced targeting of specific brain sites, improved therapeutic efficacy and lower neurotoxicity.

Keywords: Brain, nanoparticles, drug delivery, neurological treatments, diagnostics, neurodegenerative diseases, nanomedicine.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 23 May, 2017
Page: [1879 - 1896]
Pages: 18
DOI: 10.2174/1381612822666161221153228
Price: $65

Article Metrics

PDF: 43